MedTrace Logo

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

NCT06061536 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-05-13

No results posted yet for this study

Summary

A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment before.

Conditions

Interventions

DRUG

Lipovirtide 10mg

Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；

DRUG

Lipovirtide 40mg

Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；

DRUG

Lipovirtide 60mg

Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；

DRUG

DTG

DTG +3TC + TDF（once daily）.

Sponsors & Collaborators

  • Institute of Pathogen Biology, Beijing, China

    collaborator OTHER

  • Shanxi Kangbao Biological Product Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ping Ma, Doctor · Tianjin Second People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-02
Primary Completion
2024-11-29
Completion
2025-01-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06061536 on ClinicalTrials.gov